| Industry | 制造业 | ||||||||||||||||||||||||
| Company Introduction | 常州千红生化制药股份有限公司是一家专业从事生化药品的研发、生产和销售的国家高新技术企业.公司主要产品包括肝素钠原料药及制剂、胰激肽原酶制剂和门冬酰胺酶原料药及制剂.公司突破了生化药物大生产中的技术瓶颈,已将现代分子膜超滤、蛋白质亲和层析、分子螯合、病毒灭活等技术集成运用于生化酶药物和多糖类药物的大规模生产中,取得显著成效,建立了生化药物产业化技术平台.公司肝素钠原料药的质量控制水平已达到国际先进水平,并通过了欧盟COS认证及德国、澳大利亚、巴西、韩国GMP认证;公司生产的可作为依诺肝素原料的肝素产品已通过美国FDA的现场检查;"达肝素钠"原料药已获得日本厚生省的进口许可;公司胰激肽原酶原料药及制剂的产品质量内控标准已被国家药典委员会提升为国家药品标准。 | ||||||||||||||||||||||||
| Main Business | 药品生产许可证范围内的冻干粉、冻干粉针剂（含抗肿瘤药）、小容量注射剂（非最终灭菌）、片剂、硬胶囊剂、颗粒剂、原料药的研发、生产和销售。 | ||||||||||||||||||||||||
| Legal Representative | 王耀方 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 姚毅 | ||||||||||||||||||||||||
| Solicitors | 北京市德润律师事务所 | ||||||||||||||||||||||||
| Auditors | 江苏公证天业会计师事务所有限公司 | ||||||||||||||||||||||||
| Tel No | 0519-85156003 | ||||||||||||||||||||||||
| Fax No | 0519-86020617 | ||||||||||||||||||||||||
| Website | www.qhsh.com.cn | ||||||||||||||||||||||||
| stock@qhsh.com.cn | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 18/02/2011 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ 0.140 | ||||||||||||||||||||||||
| DPS(RMB)* | ¥ 0.120 | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 1.918 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 5.234B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Chiyu Banking Corporation Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |